FDA Clears Long-Acting ADHD Drug Mydayis
The US Food and Drug Administration (FDA) has approved a long-acting medication for attention-deficit/hyperactivity disorder (ADHD) from Shire called Mydayis (mixed salts of a single-entity amphetamine product). The once-daily treatment comprises three different types of drug-releasing beads and is formulated to last up to 16 hours. It is approved for adults and children aged 13 years and older with ADHD. Mydayis is is not for use in children aged 12 years and younger."
Other Articles in this Edition
FDA Clears Long-Acting ADHD Drug Mydayis
FDA approves disintegrating Cotempla tablet for ADHD
Collaboration when a Family Has ADHD: Like Parent, Like Child
What Is Intention Deficit Disorder?
5 Must-Read Articles, and an Online Course, to Help Children with ADHD
Comorbid ADHD, conduct disorder explains link between autism, violence
What’s the Link Between a Low-Income Status and a Kid’s Chance of Developing ADHD?